Brief: Sosei Says Initiates Phase 1 Trial With Novel Small-Molecule CGRP Antagonist With Biohaven

Nxera Pharma

23/06/2021 08:06

June 23 (Reuters) - SOSEI HEPTARES: 
    * SOSEI HEPTARES INITIATES PHASE 1 TRIAL WITH NOVEL
SMALL-MOLECULE
CGRP ANTAGONIST UNDER COLLABORATION WITH BIOHAVEN
    * SOSEI HEPTARES - WILL CONDUCT PHASE 1 CLINICAL TRIAL
ITSELF,
RECEIVING A MILESTONE PAYMENT FOR ITS INITIATION
    * SOSEI - INITIATES PHASE 1 TRIAL WITH NOVEL SMALL-MOLECULE
CGRP
ANTAGONIST UNDER COLLABORATION WITH BIOHAVEN
    * SOSEI HEPTARES - FIRST CLINICAL TRIAL WITH LEAD CANDIDATE
HTL0022562 (BHV3100) TO BE CONDUCTED BY SOSEI HEPTARES
    * SOSEI HEPTARES- IS ELIGIBLE FOR DEVELOPMENT COSTS FOR
CONDUCTING
TRIAL; BIOHAVEN WILL LEAD ALL FUTURE STUDIES AND DEVELOPMENT
ACTIVITIES
    * SOSEI HEPTARES - WILL BE ELIGIBLE FOR FURTHER MILESTONE
PAYMENTS
AND ROYALTIES.
    * SOSEI HEPTARES- EVENT REPORTED TODAY HAS NO SIGNIFICANT
IMPACT
ON CONSOLIDATED FINANCIAL RESULTS FOR ACCOUNTING PERIOD ENDING
31 DECEMBER 2021

Source text for Eikon:  ID:nPnbJTt70a 
Further company coverage:  BHVN.N 

 ((Reuters.Briefs@thomsonreuters.com;))